UPB · XBRL financial data

Upstream Bio financial statements, every quarter

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (UPB's year ends in late December)

In thousands of dollars	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	607	613*	566	937	683	668*	1,034	773
Research and development	15,433	21,773*	25,797	37,865	32,975	40,169*	36,565	36,089
General and administrative	4,067	5,158*	6,782	7,419	5,542	6,666*	8,084	7,052
Total operating expenses	19,500	26,931*	32,579	45,284	38,517	46,835*	44,649	43,141
Operating income (loss)	(18,893)	(26,318)*	(32,013)	(44,347)	(37,834)	(46,167)*	(43,615)	(42,368)
Interest income	2,904	5,076*	4,743	4,431	4,105	3,654*	3,054	2,659
Income tax expense (benefit)	0*	0*	0	0*	0*	0*	0	0*
Net income (loss)	(15,992)	(21,242)*	(27,270)	(39,966)	(33,748)	(42,459)*	(40,591)	(39,702)
Earnings per share, basic USD per share	(6.96)	—	(0.51)	(0.74)	(0.63)	(0.79)*	(0.75)	(0.73)
Earnings per share, diluted USD per share	(6.96)	—	(0.51)	(0.74)	(0.63)	(0.79)*	(0.75)	(0.73)
Weighted average shares, basic thousands of shares	3,023	—	53,618	53,771	53,931	54,085*	54,332	54,568
Weighted average shares, diluted thousands of shares	3,023	—	53,618	53,771	53,931	54,085*	54,332	54,568

Fiscal quarters (UPB's year ends in late December)

In thousands of dollars	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	32,948	325,892	71,312	45,458	72,164	101,578	96,724	79,397
Short-term investments	187,711	144,559	360,068	348,123	300,263	239,931	197,855	181,910
Accounts receivable	607	613	566	937	683	668	1,034	772
Prepaid and other current assets	6,007	8,096	21,841	23,754	15,907	9,620	20,666	17,523
Total current assets	227,273	479,160	453,787	418,272	389,017	351,797	316,279	279,602
Property and equipment, net	578	582	539	544	616	559	510	460
Right-of-use asset	1,914	1,783	1,649	1,511	1,368	1,222	1,071	915
Goodwill	—	0	—	—	—	—	—	—
Total assets	232,700	481,719	456,169	420,521	391,195	353,772	318,054	281,171
Accounts payable	4,899	4,041	4,718	2,551	3,952	2,726	1,710	2,314
Total current liabilities	10,874	10,737	9,567	10,929	11,908	13,452	13,669	9,988
Lease liability, non-current	1,263	1,130	992	849	703	549	390	226
Total liabilities	12,137	11,867	10,559	11,778	12,611	14,001	14,059	10,214
Accumulated deficit	(169,538)	(190,780)	(218,050)	(258,016)	(291,764)	(334,223)	(374,814)	(414,516)
Total stockholders' equity	(160,311)	469,852	445,610	408,743	378,584	339,771	303,995	270,957
Total liabilities and equity	232,700	481,719	456,169	420,521	391,195	353,772	318,054	281,171
Common shares outstanding (cover page) thousands of shares	53,597	53,641	53,794	53,909	54,039	54,420	54,420	54,771

Fiscal quarters (UPB's year ends in late December)

In thousands of dollars	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(15,992)	(21,242)*	(27,270)	(39,966)	(33,748)	(42,459)*	(40,591)	(39,702)
Stock-based compensation	1,863*	2,086*	2,635	2,597*	2,594*	2,506*	4,647	4,354*
Depreciation and amortization	14*	49*	43	42*	46*	57*	49	50*
Net cash from operating activities	(13,962)*	(19,612)*	(41,165)	(39,239)*	(22,240)*	(30,631)*	(47,852)	(35,621)*
Purchases of property and equipment	—	185*	—	—	64*	54*	—	—
Net cash from investing activities	1,409*	41,908*	(213,381)	12,773*	48,186*	58,942*	42,400	15,761*
Proceeds from issuing equity	—	—	—	—	—	—	668,800	2,100*
Net cash from financing activities	(1,641)*	270,648*	(34)	612*	760*	1,103*	598	2,533*
Net change in cash	(14,194)*	292,944*	(254,580)	(25,854)*	26,706*	29,414*	(4,854)	(17,327)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Upstream Bio	79,397	773	(35,621)*	54.8M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
Arvinas	88,000	500	(10,400)*	65.5M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
aTYR PHARMA	16,160	not reported	(9,351)*	98.1M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Arbutus Biopharma	19,171	1,014	(6,018)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
Zevra Therapeutics	122,148	37,756	10,047*	59.5M	—	Q3 FY26 10-QSep 30, 2026
Theravance Biopharma	219,766	20,731	(6,965)*	51.9M	55.7 quarters	Q2 FY26 10-QJun 30, 2026
Myriad Genetics	115,200	190,700	(8,300)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
Kura Oncology	70,242	20,874	(62,549)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	213,768	40,863	(14,455)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 2:09 PM ET. The filing on SEC.gov is the record.